Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Author
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y
Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Mahidol University; Mahidol University; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford
Type
Article
Source Title
VACCINE
Year
2022
Volume
40
Issue
39
Page
5657-5663
Open Access
Green Published, Bronze, Green Submitted
Publisher
ELSEVIER SCI LTD
DOI
10.1016/j.vaccine.2022.08.033
Format
PDF
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 mu g-than the 30 mu g-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 mu g-than the 50 mu g-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply. (C) 2022 Elsevier Ltd. All rights reserved.
Health Systems Research Institute (HSRI); National Research Council of Thailand (NRCT); Center of Excellence in Clinical Virology, Chula-longkorn University; King Chulalongkorn Memorial Hospital; Second Century Fund (C2F) of Sit-thichai Kanokudom, Chulalongkorn University
